Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Fortress Biotech (FBIO) over the last 12 years, with Q3 2025 value amounting to $6.8 million.

  • Fortress Biotech's Other Operating Expenses rose 2902.55% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year decrease of 3335.44%. This contributed to the annual value of $23.7 million for FY2024, which is 3057.11% down from last year.
  • Per Fortress Biotech's latest filing, its Other Operating Expenses stood at $6.8 million for Q3 2025, which was up 2902.55% from $6.0 million recorded in Q2 2025.
  • Fortress Biotech's Other Operating Expenses' 5-year high stood at $20.7 million during Q3 2021, with a 5-year trough of $1.4 million in Q3 2023.
  • Moreover, its 5-year median value for Other Operating Expenses was $7.2 million (2022), whereas its average is $7.6 million.
  • As far as peak fluctuations go, Fortress Biotech's Other Operating Expenses tumbled by 8061.21% in 2023, and later skyrocketed by 27750.0% in 2024.
  • Quarter analysis of 5 years shows Fortress Biotech's Other Operating Expenses stood at $9.5 million in 2021, then dropped by 18.97% to $7.7 million in 2022, then skyrocketed by 33.96% to $10.3 million in 2023, then plummeted by 76.76% to $2.4 million in 2024, then soared by 183.77% to $6.8 million in 2025.
  • Its Other Operating Expenses stands at $6.8 million for Q3 2025, versus $6.0 million for Q2 2025 and $5.9 million for Q1 2025.